Use of Autologous Conditioned Serum (ACS) for Osteoarthritis Treatment in Horses

Use of Autologous Conditioned Serum (ACS) for Osteoarthritis Treatment in Horses: A Systematic Review of Clinical Data

Vet Sci. 2023 Dec 18;10(12):707. doi: 10.3390/vetsci10120707.
Authors
Simone Della Tommasa 1 , Walter Brehm 1 , Giacomo Farì 2 , Andrea Bernetti 2 , Annarita Imperante 3
Affiliations

1 Department for Horse, University of Leipzig, 04103 Leipzig, Germany.
2 Department of Biological and Enviromental Science and Technologies (Di.Ste.B.A.), University of Salento, 73100 Lecce, Italy.
3 Field Veterinary Surgeon, 70100 Bari, Italy.

PMID: 38133258
DOI: 10.3390/vetsci10120707

Abstract

The utilization of Autologous Conditioned Serum (ACS) for treating osteoarthritis (OA) in horses has seen a notable increase in recent years. In vitro studies have consistently identified ACS as a promising therapy for OA joints, contributing to its growing popularity in OA treatment. Despite this, there is a noticeable absence of systematic reviews focused solely on the clinical data of OA patients treated with ACS, excluding the in vitro perspective. This study aims to address this gap by systematically reviewing the latest literature, concentrating solely on clinical data in in vivo studies to evaluate the efficacy of ACS in OA lesions. All clinical studies involving ACS treatments for horses with OA were included in the assessment. Surprisingly, only six trials met the inclusion criteria for this systematic review. The results indicate that the majority of the considered articles support the use of ACS as a treatment for horses, albeit with a control group provided in only one study. However, the absence of a control group and the exclusion of histological evaluation diminish the validity of the majority of clinical research. While several studies suggest a beneficial effect of ACS on OA horses without significant adverse effects, this systematic review affirms that there is no definitive evidence for its effectiveness. Therefore, further investigation of the efficacy of ACS products as a treatment for OA is warranted, emphasizing the need for more controlled trials. Poorly designed and biased studies, lacking blinding or control and adopting inadequate outcome measures, may favor positive results and, thus, necessitate a more rigorous approach to validate the efficacy of ACS in OA treatment.

Keywords: IRAP; autologous conditioned serum; horse; joint; osteoarthritis.